AN2 Therapeutics Inc.
ANTX | NASDAQ
$4.53
-$0.16 (-3.41%)
At close: Oct 30, 2026, 4:00 PM ET
$4.53
$0.00 (0.00%)
Pre-market:
Nov 2, 2026, 5:27 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 77K | n/a | n/a |
Gross Profit | n/a | n/a | n/a | -77K | n/a | n/a |
Operating Income | -38.11M | -54.55M | -69.64M | -42.26M | -21.57M | -7.28M |
Interest Income | 2.93M | 5.47M | 4.86M | 1.35M | 69K | 3K |
Pretax Income | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M | -13.6M |
Net Income | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M | -13.6M |
Selling & General & Admin | 13.34M | 14.07M | 14.76M | 12.75M | 4.67M | 1.27M |
Research & Development | 24.77M | 40.49M | 54.87M | 29.51M | 16.91M | 6.02M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 38.11M | 54.55M | 69.64M | 42.19M | 21.57M | 7.28M |
Interest Expense | n/a | n/a | n/a | 514K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 38.11M | 54.55M | 69.64M | 42.26M | 21.57M | 7.28M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 30.22M | 29.83M | 23.6M | 15.34M | 18.74M | 18.74M |
Shares Outstanding (Diluted) | 30.22M | 29.83M | 23.6M | 15.34M | 18.74M | 18.74M |
EPS (Basic) | -1.16 | -1.72 | -2.74 | -2.79 | -1.50 | -0.78 |
EPS (Diluted) | -1.16 | -1.72 | -2.74 | -2.79 | -1.50 | -0.78 |
EBITDA | -35.17M | 3.23M | 4.9M | -40.88M | -21.54M | -6.32M |
EBIT | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M | -13.6M |
Depreciation & Amortization | n/a | 54.55M | 69.64M | 77K | n/a | 7.28M |
Add to Watchlist
Select watchlists to add or remove ANTX